Skip To Main Content
Andrew Serafini Ph.D on Muck Rack

Andrew Serafini Ph.D

As seen in: JD Supra
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Andrew Serafini Ph.D’s profile

Articles by Andrew Serafini Ph.D

Navigating Key Differences in Therapeutic Antibody Patent Protection Strategies Between the United States and Europe | JD Supra

|
By Yifan Mao, Andrew Serafini Ph.D
| JD Supra
Many of today’s top-selling drugs worldwide are therapeutic antibodies thus antibody-related inventions can be extremely valuable. Developing antibody therapeutics requires significant resources and time, so it is paramount to develop a robust patent strategy to protect that investment, prevent reverse-engineering, and minimize design-arounds.
Open in Who Shared Issue with article?

Late But Not Too Late | Submitting Post-Filing Data During Patent Prosecution in Selected Jurisdictions | JD Supra

|
By Yifan Mao, Andrew Serafini Ph.D
| JD Supra
[co-authors: Kieran Williams, Ph.D. | Cotters, Clare Salisbury | Gowling WLG, Wenwen Wang, Ph.D. | Advance China IP Law Office, Glyn Truscott | Elkington +Fife, Shinichi Watanabe, M.Sc. | K. Ito & Associates, Hye-Jin Han | Kim & Chang, Malathi Lakshmikumaran Ph.D. | Lakshmikumaran & Srdharan, and Rommy Morales, M. Sc. | Olivares]* Intellectual Property counsel often face the dilemma of when to file a patent application: as soon as possible, or wait and gather more support?
Open in Who Shared Issue with article?

USPTO Announces COVID-19 Provisional Application Pilot Program | JD Supra

|
By Theodore Brown III, Andrew Serafini Ph.D
| JD Supra
The United States Patent and Trademark Office (USPTO) announced a new COVID-19 Provisional Application Pilot Program (PAPP) on Wednesday, September 16, 2020. The USPTO will defer the provisional application filing fees for up to twelve months for applications disclosing a product or process related to COVID-19 that are subject to an applicable FDA approval for COVID-19 use, whether such approval has been obtained, is pending, or will be sought prior to marketing.
Open in Who Shared Issue with article?

U.S. Patent and Trademark Office Again Extends Certain Deadlines to September 29, But Still Only For Some. | JD Supra

|
By Theodore Brown III, Andrew Serafini Ph.D
| JD Supra
Section 12004 of the CARES Act allows the director of the United States Patent & Trademark Office (USPTO) (under certain conditions) to provide temporary relief from certain USPTO filing deadlines and fees. The USPTO previously determined that the CARES Act conditions were met, and published Notices1 on May 27, 2020, extending some of the previous deadlines and fee waivers.
Open in Who Shared Issue with article?

European Patent Office COVID-19-Related Extension Period Ends Tuesday, June 2, 2020 | JD Supra

|
By Theodore Brown III, Andrew Serafini Ph.D
| JD Supra
We previously published an alert that the European Patent Office (EPO), had issued a Notice that extended the times to file papers that could not be filed due to disruptions caused by the COVID-19 pandemic. The EPO extended most deadlines accruing after March 15, 2020 until April 17, 2020, including deadlines for international applications under the PCT. We published an updated alert regarding these EPO extensions, which previously expired on April 17, 2020.
Open in Who Shared Issue with article?

U.S. Patent and Trademark Office Extends Certain Deadlines to July 1, For Some. | JD Supra

|
By Theodore Brown III, Andrew Serafini Ph.D
| JD Supra
Section 12004 of the CARES Act allows the director of the United States Patent & Trademark Office (USPTO) (under certain conditions) to provide temporary relief from certain USPTO filing deadlines and fees. The USPTO previously determined that the CARES Act conditions were met, and published new Notices1 on May 27, 2020, extending some of the previous deadlines and fee waivers.
Open in Who Shared Issue with article?

USPTO COVID19 Prioritized Examination Pilot Program PEPP Announced | JD Supra

|
By Theodore Brown III, Andrew Serafini Ph.D
| JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Open in Who Shared Issue with article?

Further Extensions for EPO Deadlines Available (Updated) | JD Supra

|
By Theodore Brown III, Andrew Serafini Ph.D
| JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Open in Who Shared Issue with article?

CARES Act - U.S. Patent and Trademark Office Extends Certain Deadlines to June 1 | JD Supra

|
By Theodore Brown III, Andrew Serafini Ph.D
| JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Open in Who Shared Issue with article?

Further Extensions for EPO Deadlines Available | JD Supra

|
By Theodore Brown III, Andrew Serafini Ph.D
| JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Open in Who Shared Issue with article?

CARES Act US Patent and Trademark Office Additional Extensions Available | JD Supra

|
By Theodore Brown III, Andrew Serafini Ph.D
| JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Open in Who Shared Issue with article?

COVID -19-Related Delays in Filing Patent and Trademark Documents | JD Supra

|
By Theodore Brown III, Andrew Serafini Ph.D
| JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Open in Who Shared Issue with article?
Show More